Few diagnoses sound as harmless as a “fatty liver.”
For many patients, the phrase is discovered accidentally. A routine ultrasound. A CT scan done for abdominal pain. A blood test showing mildly abnormal liver enzymes. In some people, it remains stable for years. In others, it becomes the first quiet chapter of a far more serious story: inflammation, scarring, cirrhosis, liver failure or liver cancer.
What many of us grew up calling non-alcoholic fatty liver disease, or NAFLD, is now more accurately described as metabolic dysfunction-associated steatotic liver disease, abbreviated MASLD. The new term is clumsy, but the thinking behind it is important.
“Non-alcoholic” defined people by what they did not have. It also created an awkward diagnosis built around denying alcohol use, as if the patient’s chief identity was suspicion. MASLD shifts attention to what is usually driving the condition: metabolic dysfunction. That means excess weight, insulin resistance, type 2 diabetes, high blood pressure, abnormal cholesterol and increased waist circumference.
The liver was caught in the crossfire of a wider metabolic storm.
A newer umbrella term, steatotic liver disease, includes several causes of fat accumulation in the liver. MASLD refers to liver fat in the presence of at least one cardiometabolic risk factor. When fat is accompanied by inflammation and liver cell injury, the condition may progress to metabolic dysfunction-associated steatohepatitis, or MASH, formerly called NASH. A further category, MetALD, recognises patients with both metabolic risk factors and alcohol intake above lower-risk thresholds.
Globally, fatty liver disease has become the most common chronic liver disorder. Estimates suggest that roughly one in three adults may be affected, with even higher rates among people living with type 2 diabetes. This is not surprising. Diabetes, obesity and MASLD are close relatives who often arrive together.
The liver sits at the centre of metabolism. It stores and releases glucose. It processes fats. It handles cholesterol. It responds to insulin. When the body becomes resistant to insulin, the liver is pushed into unhealthy patterns of fat storage and production. Fat cells, particularly those around the waist, are not passive storage bags. They produce inflammatory signals, alter hormones and contribute to vascular disease.
This is why a fatty liver should make us think not only about cirrhosis, but also about heart attacks and strokes. Many patients with MASLD are more likely to die from cardiovascular disease than from liver failure.
The tragedy is that most people feel well. There is usually no dramatic pain, no yellow eyes, no sudden collapse. The liver is a stoic organ. It works in silence and suffers in silence. By the time symptoms such as swelling of the abdomen, vomiting blood, confusion, jaundice or severe fatigue develop, the disease may already be advanced.
This is why risk-based screening matters.
People with type 2 diabetes, obesity, prediabetes, persistently abnormal liver enzymes or fatty liver seen on imaging should not be dismissed with vague advice to “lose some weight.” They need structured assessment. The aim is not to find every person with a little fat in the liver. The real task is to identify those with significant fibrosis, because scarring predicts future trouble.
A simple first step is the FIB-4 index, a calculation using age, platelet count and liver enzymes. It is not perfect, but it helps decide who can be reassured, who should be monitored and who needs further testing, such as elastography or specialist referral. A normal liver enzyme result does not always mean a healthy liver.
Evaluation should also exclude other causes of chronic liver disease: viral hepatitis, harmful alcohol use, autoimmune disease, medication-related injury, genetic disorders and other less common conditions.
Treatment begins with the unglamorous foundations: weight reduction, physical activity, better sleep, healthier eating, less alcohol and control of diabetes, blood pressure or cholesterol. These sound familiar because they work across so many chronic diseases.
Even modest weight loss can reduce liver fat. Greater weight loss may improve inflammation and scarring. Regular activity helps the liver even when the scales move slowly. The best diet is a sustainable pattern: fewer sugary drinks, fewer ultra-processed foods, less refined starch, smaller portions, more vegetables, legumes, nuts, whole grains and unsaturated fats.
There is no credible “liver detox” tea that reverses fibrosis. No herb can reliably scrub fat from the liver. Milk thistle, vitamin mixtures and expensive cleanses often do more for advertising budgets than for hepatocytes. The organ that detoxifies the body needs less metabolic abuse.
Resmetirom became the first approved treatment in the United States for selected adults with non-cirrhotic MASH and moderate to advanced fibrosis, to be used alongside diet and exercise. It is not a miracle cure and will not be suitable or available for everyone. Diabetes and obesity medications, particularly GLP-1 receptor agonists, are also reshaping the conversation by improving weight and metabolic risk, with encouraging liver-related data. Bariatric surgery may help selected patients with severe obesity.
Yet no tablet can repair the social architecture that produces disease. MASLD flourishes where cheap calories are easier to find than safe walking spaces, where working families eat what time and money permit, where stress is constant, sleep is short and health advice is delivered as scolding. Telling people to make better choices is easy. Building a society in which better choices are affordable, safe and realistic is harder.
MASLD is common, silent and potentially dangerous. It is also one of the clearest warnings the body gives before catastrophe. The liver is not accusing us. It is alerting us.
